Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2012-10, Vol.110 (7), p.984-992
Hauptverfasser: Ballantyne, Christie M., MD, Bays, Harold E., MD, Kastelein, John J., MD, PhD, Stein, Evan, MD, PhD, Isaacsohn, Jonathan L., MD, Braeckman, Rene A., PhD, Soni, Paresh N., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - blood
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Cholesterol
Clinical trials
Double-Blind Method
Eicosapentaenoic Acid - administration & dosage
Eicosapentaenoic Acid - analogs & derivatives
Eicosapentaenoic Acid - therapeutic use
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypertriglyceridemia - blood
Hypertriglyceridemia - complications
Hypertriglyceridemia - drug therapy
Lipids
Male
Medical sciences
Middle Aged
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - therapeutic use
Retrospective Studies
Statins
Time Factors
Treatment Outcome
Triglycerides - blood
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated patients with residually high triglyceride (TG) levels (≥200 and
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2012.05.031